-
05 Robert LaCaze-拜耳全球肿瘤研发及业务新方向
Robert LaCaze 总裁拜耳全球肿瘤事业部总裁Robert LaCaze is a senior bio-pharmaceutical executive with more than 28 years of experience in the industry. Throughout his career he has served in multiple operational and strategic roles involving the US, EU, China and Japan.Mr. LaCaze joined Bayer Pharmaceuticals in October 2015 and currently serves as the Executive Vice President and Head of the Oncology Strategic Business Unit (SBU). The Oncology SBU is responsible for all strategy in Bayer’s Oncology Business and consists of: Clinical Development, Regulatory Affairs, Strategic Medical Affairs, Strategic Marketing and Commercialization, Oncology Market Access and Clinical Operations. He is also a member of Bayer’s Pharmaceutical Executive Committee.Prior to joining Bayer, Mr. LaCaze spent over 25 years with Bristol Myers Squibb serving in multiple roles including his two most recent roles of Senior Vice President and Head of Product and Portfolio Strategy for Worldwide Commercialization and Senior Vice President, Global Oncology Commercialization in which he was responsible, with his R&D counterpart, for setting the vision and strategy for the Immuno-Oncology (I-O) franchise. He oversaw the early strategy for Nivolumab and lead the Global Launch of Ipilimumab BMS’s first I-O drug and the Global launch of BMS’s first target therapy, Dasatinib. Both of which have achieved more than $1B in annual sales.Mr LaCaze is a member of AACR and also serves as a member of the College of Business Advisory Board for Louisiana Tech University, his alma mater. He, his wife, and two sons reside in Robbinsville NJ.
2018-04-05 36264 看过 免费 -
03 韩国宏-介入新思路：建立 TACE 技术与靶向药物治疗最佳联合
韩国宏 教授空军军医大学（第四军医大学）西京医院消化介入科主任主任医师、教授、博导亚太原发性肝癌理事会理事（APPLE Council Member）中华医学会放射学分会介入学组副主任委员中国研究型医院学会介入专委会副主任委员中华医学会消化学分会介入协作组副组长卫计委原发性肝癌诊疗规范专家委员会委员（2011 版和 2017 版）2017 年以第一完成人获军队科技进步一等奖2016 年作为主要成员获国家科学进步奖创新团队奖2012 年至 2016 年连续五年荣登中国名医百强榜（介入放射治疗科）2010 年以来作为第一或通讯作者在 Gut、Nat Rev Gastro & Hepatol 、 Hepatology 、 J Hepatol 、 Ann Oncol 、 Clin Cancer Res 、 Radiology、 Thromb & Haemost 等权威杂志发表 SCI 同行评议论文 129 篇
2018-04-05 69705 看过 免费
热门资讯
- 骨舞健言 | 海涌教授：2024年骨质疏松症指南共识更新要点解读
- 急性胰腺炎需要抗凝吗？
- 越优例 越无忧丨化险为夷，重获新生：伊立替康脂质体（II）二线治疗晚期胰腺癌患者PFS达9个月
- 2025，医院财务审计工作指南
- 医疗设备全集成运维与管理服务（TIMMS）的实践与思考
- 越优例 越无忧丨力挽狂澜：伊立替康脂质体（II）二线治疗晚期胰腺癌助力患者实现PR
- 【新膝望】第七届风湿新秀争霸全国总结会 展示活动开启
- 瑞聚例量丨OS突破21个月，阿得贝利单抗联合治疗助力晚期肝胆管癌伴广泛腹腔转移患者生存获益
- 写好护理“敬业福”，守护健康万家春 | 新春走基层
- 北京地坛医院：节日里的最美身影 | 新春走基层
